The global consumer healthcare giant is betting big on India, reinforcing the country’s growing role in global supply chains and domestic healthcare demand.
The latest innovative move for Haleon comes with its massive ₹2,000 crore India plant, signaling a significant shift in consumer healthcare manufacturing in the country. This has also reinforced India’s growing role in global supply chains and domestic healthcare demand. The global consumer healthcare company Haleon, known for brands like Sensodyne and Centrum, has announced plans to invest nearly ₹2,000 crore in setting up its first manufacturing plant in India.
The facility will be located in Pithampur, Madhya Pradesh, and will mark a significant expansion of the company’s local footprint. The investment is expected to unfold over the next few years, with operations likely beginning by 2028. This will be Haleon’s first wholly owned manufacturing site in the country, marking a move beyond its earlier reliance on third-party production.
Why is India becoming a key market for global healthcare firms?
India has rapidly emerged as one of the fastest-growing consumer healthcare markets globally. Rising health awareness, expanding middle-class consumption, and stronger rural penetration have made the country a strategic growth destination for multinational healthcare companies.
For Haleon, India is already its second-largest oral care market worldwide. Industry estimates suggest India’s consumer health market could cross £23 billion by 2030, making local manufacturing increasingly important for cost efficiency and supply chain resilience.
The bigger push for local manufacturing.
The new facility aligns with India’s larger push toward domestic manufacturing under the “Make in India” framework. With global companies diversifying away from concentrated supply chains, India is becoming an attractive production hub for both local demand and exports. Haleon’s upcoming plant will primarily focus on oral healthcare products and may also support exports to wider Asian markets. The project is expected to create around 500 direct jobs, while also strengthening regional industrial infrastructure.
Haleon’s investment reflects a broader trend: healthcare manufacturing is increasingly moving closer to high-demand markets. For India, this not only boosts employment and production capacity but also signals growing confidence from global healthcare leaders. As multinational companies expand their manufacturing base in India, the country’s role in global healthcare and wellness supply chains is expected to become far more significant in the years ahead.
